Overview Study details Eligibility Things to know Research Study plan

Simplify with AI

Overview Study details Eligibility Things to know Research Study plan

Simplify with AI

Locally Optimised Contouring With AI Technology for Radiotherapy

NARECRUITING

LOCATOR is a multicentre phase II randomised clinical trial that is looking at the process of contouring in radiation treatment for breast cancer patients. This study looks at whether contouring aided by artificial intelligence (AI) is comparable in quality to that of contouring done completely manually by a radiation oncologist. We are also looking at whether AI assisted contouring saves radiation oncologists time when compared to fully manual contouring.

LOCATOR uses the LOCATOR software which is an in-house software developed locally and trained on local data.

Study details:

LOCATOR is a multicentre phase II non-inferiority randomised controlled trial looking at comparing AI assisted contours (with in-house LOCATOR software) against fully manual contouring in breast cancer patients. The primary endpoint is to show non inferiority in grade of AI assisted contouring when compared to fully manual contouring with a poor contour (score \<= 2) as per the MD Anderson Contouring Grade Scale. Secondary endpoints include geometric assessments of contour accuracy, dosimetric differences based on contours, performance (geometric) when compared to commercially available tools as well as economic cost-benefit analysis if in-house AI contouring tools.

The study will randomise patients 3:1 to the intervention arm of LOCATOR assisted contours to manual contours. An initial AI contouring model for each tumor type will be trained on contours from 45 previous breast cases using a nnUNetv2 framework. The model will then be iteratively updated every 20-50 patients.

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

18 years and older who are planned for primary breast malignancy
ECOG performance 0-2
Ability to understand and willingness to sign a written informed consent document
The target volume must be able to be objectively reviewed by current published national or international clinical guidelines

Exclusion criteria

Patients under 18 years of age
Patients unable to understand consent documents

Eligibility

Age eligible for study : NA

Healthy volunteers accepted : No

Gender eligible for study: ALL

Things to know

Study dates

Study start:

Primary completion:

Study completion finish:

Study type

TREATMENT

Phase

Study ID

NCT06546592

Intervention or treatment

DEVICE: AI assisted contouring

Conditions

Contouring
Segmentation
Radiation Therapy
Artificial Intelligence
Deep Learning

Condition: Contouring, Segmentation and more
DEVICE: AI assisted contouring
Dubbo, New South Wales, Australia and more
Sponsor: Royal North Shore Hospital

Save

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial?

If you're a clinic or sponsor, you can claim this study

Research sites nearby

Closest Location:

Western Cancer Centre Dubbo

Select from list below to view details:

Western Cancer Centre Dubbo
Dubbo, New South Wales, Australia
Central West Cancer Centre
Orange, New South Wales, Australia
Department of Radiation Oncology, Royal North Shore Hospital
St Leonards, New South Wales, Australia

Loading map...

Who is running the clinical trial?

RNSH

Royal North Shore Hospital

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: AI assisted contouring Patients in this arm will have their contours/segmentations generated by a combination of the LOCATOR (AI) software before manual edits and checks by a radiation oncologist.	Device: AI assisted contouring
NO_INTERVENTION: Manual contouring Patients in this arm will have standard of care which is fully manual contours/segmentations generated and checked by a radiation oncologist.

What is the study measuring?

Primary Outcome

Measure	Description	Time Frame
Assessment of differences in Contour Quality	To assess the contour quality of fully manual segmentation vs AI assisted segmentation. This assessment will be done using the MD Anderson Cancer Centre five-point likert scale used to validate autosegmentation models ranging from (Strongly disagree to Strongly Agree). The measure will be the proportion of unacceptable contours (as defined by MD Anderson autocontouring score \<= 2) between manual contouring and AI-assisted contouring.	18 months

Secondary Outcome

Measure	Description	Time Frame
Assessment of quality of AI assisted contours with and without manual edits	To assess the contour quality of AI assisted contours with and without manual edits. This assessment will be done using the MD Anderson Cancer Centre five-point likert scale used to validate autosegmentation models ranging from (Strongly disagree to Strongly Agree). The measure will be the proportion of unacceptable contours (as defined by MD Anderson autocontouring score \<= 2) between manual contouring and AI-assisted contouring.	18 months
Time Savings	To evaluate the difference in time taken to contour with and without the assistance of an auto-segmentation tool.	18 months
To assess the differences in acute clinician reported toxicity between patients treated with contours assisted by AI contouring versus manual contouring.	Acute clinician reported toxicity will be measured using CTCAE version 5.0 across individual items (see full protocol appendix). For this study, the outcome will be the difference in the proportion of patients with grade≥3 toxicity at any point in time from the start of radiotherapy to 90 days following radiotherapy.	18 months
To assess the differences in late clinician reported toxicity between patients treated with contours assisted by AI contouring versus manual contouring.	Late clinician reported toxicity will be measured using CTCAE version 5.0 across individual items (see full protocol appendix). For this study, the outcome will be the difference in the proportion of patients with grade≥3 toxicity at any point in time between 90 days following radiotherapy and 5 years following radiotherapy.	5 years
To assess the differences in patient reported general acute quality of life outcomes between patients treated with contours assisted by AI contouring versus manual contouring.	General acute patient quality of life outcomes will be measured using the EORTC QLQ-C30 instrument. For this study, the outcome will be the difference in total scores and by domain at any point in time from the start of radiotherapy to 90 days following radiotherapy.	18 months
To assess the differences in patient reported general late quality of life outcomes between patients treated with contours assisted by AI contouring versus manual contouring.	Acute patient reported toxicity will be measured using the EORTC QLQ-C30 and QLQ-BR45. For this study, the outcome will be the difference in total scores and by domain at any point in time between 90 days following radiotherapy and 5 years following radiotherapy.	5 years
To assess the differences in patient reported breast specific acute quality of life outcomes between patients treated with contours assisted by AI contouring versus manual contouring.	Breast specific acute patient quality of life outcomes will be measured using the EORTC QLQ-BR45 instrument. For this study, the outcome will be the difference in total scores and by domain at any point in time from the start of radiotherapy to 90 days following radiotherapy.	18 months
To assess the differences in patient reported breast specific late quality of life outcomes between patients treated with contours assisted by AI contouring versus manual contouring.	Breast specific late patient quality of life outcomes will be measured using the EORTC QLQ-BR45 instrument. For this study, the outcome will be the difference in total scores and by domain at any point in time between 90 days following radiotherapy and 5 years following radiotherapy.	5 years
Assessment of accuracy of AI assisted contours before and after manual edits using surface dice similarity coefficient (sDSC).	To assess accuracy (geometrically) of AI segmentation before and after manual correction. This will be done by comparing the change in surface dice similarity coefficient (sDSC).	18 months
Assessment of accuracy of AI assisted contours before and after manual edits using dice similarity coefficient (DSC).	To assess accuracy (geometrically) of AI segmentation before and after manual correction. This will be done by comparing the change in dice similarity coefficient (DSC).	18 months
Assessment of accuracy of AI assisted contours before and after manual edits using added path length (APL)	To assess accuracy (geometrically) of AI segmentation before and after manual correction. This will be done by comparing the change in APL.	18 months
Assessment of accuracy of AI assisted contours before and after manual edits using mean slice-wise Hausdorff distance (MSHD).	To assess accuracy (geometrically) of AI segmentation before and after manual correction. This will be done by comparing the change in MSHD.	18 months
Assessment of dosimetric differences in plans optimised on AI assisted contours before and after manual edits.	We will assess dosimetric differences to the clinical tumour volume (CTV), planning target volume (PTV) and organs at risk (OARs) between AI assisted contours before and after manual edits. The measure will be in the proportion of patients who pass all planning constraints as per the FAST FORWARD protocol.	18 months
Assessment of accuracy in contours with an initial and retrained AI model using surface dice similarity coefficient (sDSC).	To assess improvements, if any, in accuracy (geometrically) on contours generated on an initial AI model versus models re-trained on clinical trial data every 20-50 patients. Comparisons will be made using the change in surface dice similarity coefficient (sDSC) when the initially generated AI contour is compared with the final edited contour.	18 months
Assessment of accuracy in contours with an initial and retrained AI model using dice similarity coefficient (DSC).	To assess improvements, if any, in accuracy (geometrically) on contours generated on an initial AI model versus models re-trained on clinical trial data every 50-100 patients. Comparisons will be made using the change in dice similarity coefficient (DSC) when the initially generated AI contour is compared with the final edited contour.	18 months
Assessment of accuracy in contours between different AI systems using surface dice similarity coefficient (sDSC).	To compare the accuracy of an in-house AI segmentation tool (LOCATOR) against commercially available tools on geometric accuracy. Comparisons will be made using the difference in surface dice similarity coefficient (sDSC) with the initially generated AI contours when compared with the final manual contour.	18 months
Assessment of accuracy in contours between different AI systems using dice similarity coefficient (DSC).	To compare the accuracy of an in-house AI segmentation tool (LOCATOR) against commercially available tools on geometric accuracy. Comparisons will be made using the difference in dice similarity coefficient (DSC) with the initially generated AI contours when compared with the final manual contour.	18 months
Assessment of quality in contours between different AI systems	To compare the quality of contours of an in-house AI segmentation tool (LOCATOR) against commercially available tools. This assessment will be done using the MD Anderson Cancer Centre five-point likert scale used to validate autosegmentation models ranging from (Strongly disagree to Strongly Agree). The measure will be the proportion of unacceptable contours (as defined by MD Anderson autocontouring score \<= 2) between manual contouring and AI-assisted contouring.	18 months
Assessment of patient perception and attitudes on AI use in their care	We will perform a brief assessment of patient perception on AI use in their care with a six question survey following their treatment on a five-point likert scale (strongly agree to strongly disagree).	18 months
Economic Cost Benefit Analysis	To perform an economic cost-benefit analysis of using an in-house auto-segmentation (LOCATOR) tool compared to manual segmentation and commercial auto-segmentation systems. This will be done using direct dollar (US and Australian) cost comparisons. Direct costs will be calculated for the LOCATOR system including labor, hardware and maintenance costs for 1 and 3 years. The direct dollar cost for a commercial system will be compared against the overall direct cost of the LOCATOR system. The direct cost of retaining a manual system will be calculated based on the direct cost of extra hours of labor required.	18 months

Are you running this trial?If you're a clinic or sponsor, you can claim this study.

Claim this trial

References

Clinical Trials Gov: Locally Optimised Contouring With AI Technology for Radiotherapy

Other trials to consider

Loading suggested trials...